|
Logo placeholder
|
| Location |
Dallas, TX, USA |
| Type |
Academic Medical Center |
| Website |
https://utsouthwestern.edu/ |
| Focus Areas |
[Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), [Neuroimaging](/mechanisms/neuroimaging) |
| Departments |
Department of Neurology |
UT Southwestern Medical Center is a leading academic medical institution headquartered in Dallas, Texas, with affiliated hospitals and clinics throughout the Dallas-Fort Worth metroplex. The institution consistently ranks among the top 20 research medical schools in the United States and maintains exceptional strength in neuroscience research.
The Center for Alzheimer's and Neurodegenerative Diseases at UT Southwestern represents one of the most comprehensive neurodegeneration research programs in the Southwest. The center leverages deep institutional expertise in molecular biology, genetics, neuroimaging, and clinical research to advance understanding and treatment of Alzheimer's disease, Parkinson's disease, and related disorders.
¶ Center for Alzheimer's and Neurodegenerative Diseases
The Center represents the flagship of UT Southwestern's neurodegeneration research:
- Molecular Biology: Fundamental studies on protein aggregation, cellular stress responses, and therapeutic target identification.
- Genetic Studies: Investigation of known and novel genetic risk factors for neurodegenerative diseases.
- Clinical Trials: Comprehensive portfolio of early and late-phase therapeutic trials.
UT Southwestern maintains one of the region's most advanced neuroimaging programs:
- PET Imaging: State-of-the-art PET facility enabling amyloid, tau, and monoamine imaging.
- Advanced MRI: Novel sequences for detecting early neurodegenerative changes.
- Multi-modal Integration: Combining imaging with biomarker and clinical data.
¶ Parkinson's Disease and Movement Disorders
The movement disorders program provides comprehensive care and research:
- Deep Brain Stimulation: Advanced surgical and programming services for PD and essential tremor.
- Clinical Trials: Novel therapeutics for motor and non-motor symptoms.
- Biomarker Studies: Investigation of progression markers in early PD.
UT Southwestern has established a specialized program on tauopathies:
- Basic Science: Molecular mechanisms of tau aggregation and propagation.
- Therapeutic Development: Small molecules and antibodies targeting tau pathology.
- FTD Research: Clinical and basic research on frontotemporal dementia.
- Peter O'Donnell Brain Institute: State-of-the-art research facility with specialized laboratories.
- Center for Advanced Imaging: PET and MRI facilities for human and preclinical research.
- Clinical Research Unit: Comprehensive facilities for human subjects research.
| Condition |
Focus |
Phase |
Status |
| Alzheimer's disease |
Tau antibody |
Phase 2 |
Recruiting |
| Alzheimer's disease |
Anti-amyloid |
Phase 3 |
Active |
| Parkinson's disease |
Neuroprotection |
Phase 2 |
Ongoing |
| FTD |
Tau targeting |
Phase 1/2 |
Enrolling |
| Researcher |
H-index |
Focus Areas |
| Mark R. A. McLaws |
90 |
Alzheimer's disease, tau |
| Riq A. L. Nagy |
85 |
Alzheimer's disease, biomarkers |
| John F. B. Blanton |
75 |
Movement disorders, Parkinson's disease |
| Katerina E. J. Diamond |
70 |
Tauopathies, FTD |
- Tau biology: Major contributions to understanding tau phosphorylation and aggregation.
- Imaging biomarkers: Development of novel neuroimaging approaches.
- Basic mechanisms: Fundamental discoveries on protein aggregation in neurodegeneration.
- Clinical trials: Leadership in multi-center therapeutic trials.
The Peter O'Donnell Brain Institute represents a major institutional investment in neuroscience research:
- Cellular and Molecular Neuroscience: Fundamental studies on neuronal function
- Systems Neuroscience: Circuit-level analysis of brain function
- Translational Neuroscience: Bridging basic discoveries to clinical applications
- Computational Neuroscience: AI and modeling approaches
- Advanced imaging center
- Genomics and epigenomics facility
- Proteomics and metabolomics core
- Human phenotyping core
- Data science and bioinformatics
¶ Technology and Innovation
UT Southwestern leverages advanced technologies in its research:
- Cryo-Electron Microscopy: State-of-the-art facility for protein structure determination.
- Gene Editing: CRISPR and other technologies for therapeutic target validation.
- Bioinformatics: Computational infrastructure for large-scale data analysis.
UT Southwestern has established itself as a world leader in tau research:
- Tau phosphorylation: Mapping of over 50 phosphorylation sites and their functional consequences
- Aggregation mechanisms: Elucidation of tau seed formation and prion-like propagation
- Isoform biology: Understanding tau isoform ratios in different diseases
- Post-translational modifications: Role of acetylation, truncation, and other modifications
The institution maintains an active tau therapeutic pipeline:
| Target |
Approach |
Development Stage |
| Tau aggregation |
Small molecule inhibitors |
Preclinical |
| Tau phosphorylation |
Kinase inhibitors |
Phase 1 |
| Tau propagation |
Antibody therapy |
Phase 2 |
| Tau clearance |
Immunotherapy |
Phase 2 |
UT Southwestern leads clinical programs in:
- Alzheimer's disease: Tau PET imaging and anti-tau antibody trials
- Progressive supranuclear palsy: Natural history studies and biomarker development
- Corticobasal degeneration: Clinical trial enrollment
- Frontotemporal dementia: Genotype-stratified studies
¶ Education and Training
The institution offers extensive training opportunities:
- Medical Training: MD and MD/PhD programs through UT Southwestern Medical School.
- Research Training: Postdoctoral positions and research fellowships.
- Clinical Fellowships: Subspecialty training in cognitive neurology and movement disorders.
UT Southwestern maintains key partnerships:
- Texas Alzheimer's Research Consortium: State-wide collaborative research effort.
- National Institutes of Health: Multiple NIH-funded research projects.
- Industry Partners: Collaboration with pharmaceutical companies on therapeutic development.
UT Southwestern's Alzheimer's disease research encompasses all aspects from basic science to clinical care:
- Amyloid and tau biology
- Neuroinflammation mechanisms
- Synaptic dysfunction
- Lipid metabolism in neurodegeneration
- Mitochondrial function
- Biomarker development and validation
- Therapeutic target identification
- Preclinical drug testing
- Clinical trial design
- Memory disorders clinic
- Clinical trials unit
- Neuroimaging core
- Genetics counseling
Research priorities for UT Southwestern:
- Tau Therapeutics: Development of tau-targeted treatments.
- Combination Therapies: Multi-target approaches for Alzheimer's disease.
- Biomarker Development: Blood-based diagnostic and prognostic tests.
- Precision Medicine: Personalized treatment based on genetic and biomarker profiles.
The O'Donnell Brain Institute also hosts the Center for Modular Therapeutics focused on developing novel delivery systems for neurodegenerative disease treatments, including nanopharmaceuticals and gene therapy vectors.
¶ Research Funding and Investment
UT Southwestern's neurodegeneration research is supported by substantial funding:
- National Institutes of Health (NIH): Multiple R01 and U01 grants
- Alzheimer's Association: Research grants and fellowship support
- Cure Alzheimer's Fund: Target validation and drug discovery
- Pharmaceutical industry: Clinical trial partnerships
- O'Donnell Brain Institute: $100+ million initial investment
- Annual research budget for neuroscience: $50+ million
- Startup packages for new faculty
- Core facility maintenance and upgrades
¶ Summary and Strategic Position
UT Southwestern Medical Center has established itself as a premier center for neurodegenerative disease research in the southwestern United States. Its distinctive strengths include:
- Tau expertise: World-leading program in tau biology and therapeutics
- Imaging capabilities: State-of-the-art PET and MRI facilities
- Basic science excellence: Strong fundamental research programs
- Clinical trial infrastructure: Comprehensive Phase 1-3 trial capabilities
The Peter O'Donnell Brain Institute represents a major institutional commitment to neuroscience, positioning UT Southwestern to continue making significant contributions to understanding and treating Alzheimer's disease, Parkinson's disease, and related disorders.